A summary in Thursday's BIO SmartBrief incorrectly stated that a new amphetamine from New River Pharmaceuticals and to be sold by Shire Pharmaceuticals might have difficulty making it to market. New River has presented positive data on the drug, NRP104, but some investors and analysts say the FDA and Drug Enforcement Administration may be less lenient in their classifications because of fears of drug abuse. SmartBrief regrets the error.

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC